Ultiva痛速寧

Ultiva

remifentanil

Manufacturer:

Aspen Pharmacare Asia

Distributor:

Cordial Trading
/
Primal
Concise Prescribing Info
Contents
Remifentanil HCl
Indications/Uses
As an analgesic agent for use during induction &/or maintenance of general anaesth under close supervision. Provision of analgesia & sedation in mechanically ventilated intensive care patients ≥18 yr.
Dosage/Direction for Use
General anaesth Adult Induction: 0.5-1 mcg/kg/min as infusion, w/ or w/o an initial bolus inj of 1 mcg/kg over not <30 sec. Maintenance in ventilated patients: Rate can be titrated upward in 25-100% increments or downward in 25-50% decrements, every 2-5 min to attain the desired level of μ-opioid response. Spontaneous breathing anaesthetized patients w/ a secured airway: Initially 0.04 mcg/kg/min as infusion. Discontinuation/continuation into immediate post-op: Infusion rate should initially be decreased to a rate of 0.1 mcg/kg/min in patients who are breathing spontaneously. Childn 1-12 yr Maintenance: 0.25 mcg/kg/min as infusion. Cardiac anaesth Induction: 1 mcg/kg/min. Maintenance: Rate can be titrated upward in 25-100% increments or downward in 25-50% decrements, every 2-5 min according to patient need. Intensive care Initially 0.1-0.15 mcg/kg/min, may be titrated in increments of 0.025 mcg/kg/min.
Contraindications
Hypersensitivity to any component of the preparation & other fentanyl analogues. Epidural & intrathecal use. Not for use as a sole agent for induction of anaesth.
Special Precautions
Debilitated, hypovolaemic patients & elderly. Pregnancy & lactation. Hypersensitivity to opioids of a different class. Use in mechanically ventilated intensive care patients is not recommended for duration of treatment >3 days. Muscle rigidity; marked resp depression; dependency. Can impair cognitive function & can affect a patient's ability to drive safely. Neonates/infants <1 yr.
Adverse Reactions
Acute resp depression, bradycardia, hypotension &/or skeletal muscle rigidity. Post-op shivering, apnoea, hypoxia, pruritus, constipation, sedation, nausea & vomiting. Post-op HTN & aches.
Drug Interactions
Decreases amounts or doses of inhaled & IV anaesth & benzodiazepines required for anaesth. Increased incidence of adverse effects w/ CNS depressants if their doses are not reduced. Exacerbated CV effects w/ cardiac depressant drugs eg, β-blockers & Ca-channel blocking agents.
MIMS Class
Anaesthetics - Local & General
ATC Classification
N01AH06 - remifentanil ; Belongs to the class of opioid anesthetics. Used as general anesthetics.
Presentation/Packing
Form
Ultiva inj 1 mg
Packing/Price
5 × 1's
Form
Ultiva inj 2 mg
Packing/Price
5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in